<div id="readability-page-1">Virax Biolabs Group Limited ( VRAX ) shares are trending on Tuesday. VRAX shares rose 17.36% to $0.28 in after-hours trading on Monday. The jump in the late trading session follows an intraday gain of 53.09%, closing the stock at $0.24, according to Benzinga Pro data. <h2>Armistice Capital Takes 4.99% Stake in VRAX</h2> On May 15, Armistice Capital, LLC, a New York-based hedge fund, filed a Securities and Exchange Commission disclosure revealing a 4.99% beneficial ownership stake of over 1 million ordinary shares. The fund was founded in 2012 by Managing Member Steven Boyd, who signed the filing. Last month, Virax Biolabs ( VRAX ) announced it is advancing ViraxImmune, a proprietary assay targeting post-acute infection syndromes including Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a space the company estimates carries a U.S. economic burden exceeding $25 billion. <h2>Trading Metrics, Technical Analysis</h2> Virax, an innovative biotechnology company, has a market capitalization of $4.79 million. Its stock has traded between a 52-week high of $1.18 and a 52-week low of $0.10. VRAX's Relative Strength Index (RSI) is 69.52. Over the past 12 months, the stock of the biotech has dropped 78.04%. Currently, VRAX is positioned at about 13% of the way up from its 52-week low to its high, meaning the stock is trading closer to its annual low. Benzinga’s Edge Stock Rankings indicate that VRAX has a negative price trend across all time frames. &lt;figure class=&#34;wp-block-image aligncenter size-full is-resized&#34;&gt;<img width="436" height="270" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/19005012/image-485.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/19005012/image-485.png"/>&lt;/figure&gt; Photo Courtesy: Gorodenkoff on Shutterstock.com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Read Also: Bakkt (BKKT) Stock Jumps Over 16% After Hours: Here's Why The ICE-Backed Crypto Platform Is Trending Overnight </div>

VRAX

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

Virax Biolabs (VRAX) 的股票在盤後交易中上漲了 17.36%，達到 0.28 美元，此前在日內交易中上漲了 53.09%。Armistice Capital 披露其在 VRAX 中持有 4.99% 的股份。該公司正在推進 ViraxImmune，旨在針對急性感染後綜合症。儘管市值為 479 萬美元，但 VRAX 的股票在過去一年中下跌了 78.04%，交易價格接近其 52 周低點 0.10 美元

為什麼 Virax Biolabs (VRAX) 的股票在夜間成為熱門話題？